SophiA GENETICS Launches Global Consortium, SOPHIA UNITY, to Accelerate Cancer Research, Drug Development and Data-Driven Patient Care

New collective intelligence network to enable cutting-edge oncology research in support of precision medicine

BOSTON and ROLES, Switzerland, May 30, 2024 /CNW/ — SOPHIA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPhIA UNITY, a new data-driven consortium, created to accelerate cancer research globally. SOPHIA UNITY aims to bring together leading healthcare institutions to advance a common goal to advance cancer research, advance drug development and support data-driven patient care.

To advance the adoption of precision oncology, it is essential to have access to large-scale data from a wide range of modalities (such as imaging, genomics, pathology and clinical notes) and diverse sets of patient profiles. Currently, no single institution globally collects the volume and diversity of information needed to advance the field of healthcare. SOPHIA GENETICS has launched SOPHIA UNITY to respond to this need and meet the demand for high-quality and diverse data at scale, aiming to drive a new era of precision oncology research.

The collective intelligence network will advance research initiatives using SOPhiA CarePath™, the multimodal module in the SOPhiA DDM™ platform, to collect and analyze complex real-world data. This data will be harmonized and curated using advanced AI-based technology and proprietary algorithms of SOPhiA GENETICS. Through SophiA GENETICS’ unique platform and CarePath™ offering, SOPhiA UNITY members will have access to meaningful, data-driven insights that will support decision-making and accelerate oncology research.

“At SophiA GENETICS, we have mastered the challenge of harmonizing and linking genomic data and have the capabilities to do the same with other modalities through our CarePath™ module,” said Jurgi Camblong, PhD., Co-Founder and CEO of SophiA GENETICS . “SophiA UNITY will usher in the next era of precision medicine innovation by bringing together best-in-class institutions that are dedicated to advancing oncology research and the use of data-driven medicine. We are extremely optimistic about the insights of this intelligence collective network will generate to advance our common goal.”

SOPHIA GENETICS announced that the first member to join SOPHIA UNITY is Memorial Sloan Kettering Cancer Center, a premier cancer treatment and research facility and world leader in patient care, research and educational programs. Additional members will be announced in the coming months.

The story continues

“I look forward to participating in the new data-driven consortium and collaborating with other institutions to derive deeper insights from our collective data,” said Mrinal GounderMD, Sarcoma Oncologist and Early Drug Development Specialist and Ambassador Physician to INDIA AND AsiaMemorial Sloan Kettering Cancer Center.

Leading academic cancer centers seeking to connect with like-minded researchers globally are eligible to join the SOPhiA UNITY collective intelligence network and gather knowledge that can be applied locally. For more information, visit SOPHIAGENETICS.COMor connect LinkedIn.

About Sophia GENETICS
SOPHIA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company with a mission to expand access to data-driven medicine using AI to deliver world-class care to patients with cancer and health disorders. rare across the globe. It is the creator of the SOPhiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time actionable insights for a broad global network of hospital, laboratory and biopharma institutions. For more information, visit SOPHIAGENETICS.COM and connect with us LinkedIn.

SophiA GENETICS products are for research use only and not for use in diagnostic procedures unless otherwise specified. The information in this press release relates to products that may or may not be available in various countries and, if applicable, may or may not have received approval or market authorization from a government regulatory body for indications different for use. Please contact [email protected] to obtain the correct product information for your country of residence.

Sophia GENETICS Forward-looking Statement:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, and management’s plans and objectives for operations future, are forward-looking. statements. Forward-looking statements are based on the beliefs and assumptions of our management and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in forward-looking statements due to various factors, including those described in our filings with the Securities and Exchange Commission. USA. No assurance can be given that such results will be achieved in the future. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any changes in our expectations or any changes in the events, conditions or circumstances on which such statements are based, except as required to do so. do so by force. the law. No representation or warranty (express or implied) is given as to the accuracy of any such forward-looking statements.

Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHIA GENETICS.

View original content to download multimedia: https://www.prnewswire.com/news-releases/sophia-genetics-launches-global-consortium-sophia-unity-to-accelerate-cancer-research-drug-development-and- date -driven-patient-care-302159680.html

SOURCE SophieA GENETICS

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2024/30/c7968.html